JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00

Dyne Therapeutics (NASDAQ:DYN) had its target price lowered by equities research analysts at JPMorgan Chase & Co. from $17.00 to $16.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential downside of 3.59% from the company’s previous close.

DYN has been the subject of several other reports. Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Morgan Stanley increased their price target on Dyne Therapeutics from $46.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, December 8th. Chardan Capital reiterated a “buy” rating and issued a $38.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 target price on shares of Dyne Therapeutics in a report on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $38.41.

Dyne Therapeutics Stock Down 0.6%

Shares of Dyne Therapeutics stock traded down $0.11 during trading hours on Tuesday, reaching $16.60. The company’s stock had a trading volume of 553,863 shares, compared to its average volume of 2,101,134. The company has a market capitalization of $2.37 billion, a P/E ratio of -4.53 and a beta of 1.32. The stock’s fifty day simple moving average is $19.49 and its two-hundred day simple moving average is $15.57. Dyne Therapeutics has a one year low of $6.36 and a one year high of $25.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.05. On average, research analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. CWM LLC increased its stake in shares of Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock worth $29,000 after purchasing an additional 1,900 shares during the last quarter. Chung Wu Investment Group LLC purchased a new position in Dyne Therapeutics in the third quarter valued at approximately $30,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares during the period. Ameritas Investment Partners Inc. increased its position in Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock worth $91,000 after buying an additional 955 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.